Dyve Biosciences is proud to announce FDA clearance to initiate phase 2 study of DYV-700 for treatment of acute #gout pain.
Full press release: https://t.co/KLO5r9OFEb
Thank you to @MassDevice for highlighting Dyve's press release announcing first patient enrollment in Phase 2 TARGETS Study for Acute Gout: https://t.co/Z7Y4X5Uh1o
#gout#biotech#clinicaltrials
Thank you @Machiz and @Nasdaq for featuring Dyve in their #NasdaqSpotlight series in New York City last week! You can view the full interview with CEO Ryan Beal on Dyve's website: https://t.co/2kjYnPvCDW
#biotech#healthcare
First subjects were enrolled in Dyve's Phase 2 TARGETS study this week! Thank you to all of our partners for making this achievement possible. It is an exciting milestone for our company! #gout#biotech
BIO is helping leaders fulfill that commitment by providing resources to help build a more inclusive and diverse workforce. Learn more at https://t.co/yzJvmznVct #rightmixmatters
Dyve is thrilled to welcome longtime Pfizer Executive Chuck Harbert, Ph.D. to the company in the role of Chief Scientific Officer.
Full press release: https://t.co/58c6jPKyQQ
Learn more about Dyve: https://t.co/70R8IENiT4
@mikewill91 Thanks for the interest @mikewill91! You can get in touch with us through our contact page: https://t.co/1yc7RYFTKh and someone from our team will reach out to connect.
Dyve Biosciences is proud to announce FDA clearance to initiate phase 2 study of DYV-700 for treatment of acute #gout pain.
Full press release: https://t.co/KLO5r9OFEb
When should lasers be used to treat #melasma? Mildred López Piñeiro, M.D. provides her insight in our new column on energy devices. https://t.co/yHK8KEOGOo
Dyve's SAB member Smitha Reddy, MD with CEO Ryan Beal, MD before Dr. Reddy's poster presentation at #ACR19 in Atlanta.
For the complete poster, visit our publications page on our website:
https://t.co/aTgLRDCXjd